Results 61 to 70 of about 79,249 (245)
ABSTRACT Objective Glioma recurrence severely impacts patient prognosis, with current treatments showing limited efficacy. Traditional methods struggle to analyze recurrence mechanisms due to challenges in assessing tumor heterogeneity, spatial dynamics, and gene networks.
Lei Qiu +10 more
wiley +1 more source
Irinotecan in the treatment of colorectal cancer. A literature review
In 1998, oncologists got a brand new antitumor drug – irinotecan. It’s been already 18 years since its approval for second-line polychemotherapy of metastatic colorectal cancer.
V. A. Ivanov +6 more
doaj +1 more source
Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model. [PDF]
Relapsed osteosarcoma is a recalcitrant tumor. A patient's cisplatinum (CDDP)-resistant relapsed osteosarcoma lung metastasis was previously established orthotopically in the distal femur of mice to establish a patient-derived orthotopic xenograft (PDOX)
Dry, Sarah M. +23 more
core +1 more source
A novel sample holder compatible with the Zeiss Lightsheet 7 microscope improves imaging of spheroids embedded in collagen matrices. By enabling dual‐sided illumination, it enhances image quality and quantitative analysis of migrating cells. This method advances 3D light sheet microscopy for studying tumor invasion and therapeutic responses.
Masoumeh Mohamadian Namaqi +5 more
wiley +1 more source
Objectives The hepatotoxicity of irinotecan has been widely implicated in the treatment of multiple solid tumours. However, there are few studies on the influencing factors of irinotecan-induced hepatotoxicity.
Yi Xu +9 more
doaj +1 more source
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma. [PDF]
Lessons learnedThe safety profile in the patient groups who received FOLFIRI and simtuzumab did not differ from that in the FOLFIRI and placebo group.The addition of simtuzumab to chemotherapy with FOLFIRI does not improve clinical outcomes in patients ...
Bendell, Johanna +5 more
core +1 more source
Homoisoflavanone (HIF), a bioactive compound isolated from Polygonatum kingianum, selectively suppresses colorectal cancer progression by inducing DNA damage‐mediated mitochondrial apoptosis and parthanatos‐like cell death. HIF triggers mitochondrial dysfunction, including depolarized membrane potential, elevated ROS, and ATP depletion, while impairing
Hongjie Fan +12 more
wiley +1 more source
Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer. [PDF]
Thus, we evaluated the immunofluorescence pattern of TRAIL-receptors and E-cadherin to assess the fraction of membrane-bound TRAIL-receptors in 231 selected patients with early-stage CRC undergoing surgical treatment only.
De Toni, Enrico N. +10 more
core +3 more sources
The age‐associated disparity of nanocarrier biodistribution limits the nanotherapeutics of childhood solid tumors. This study developed an ultrasound‐activated liposomal prodrug (CSCPTL) to overcome the age‐associated disparity of off‐target distribution.
Danfei Chen +8 more
wiley +1 more source
Background Despite initial dramatic responses, metastatic small cell lung cancer (SCLC) invariably recurs. Irinotecan is one of the active agents for patients with recurrent SCLC.
Feride Yılmaz +9 more
doaj +1 more source

